Rare Gastrointestinal Diseases Treatment Market Size is valued at USD 1.29 Bn in 2022 and is predicted to reach USD 1.68 Bn by the year 2031 at a 3.1% CAGR during the forecast period for 2023-2031.
Rare gastrointestinal disorders are those that affect the GI (gastrointestinal tract) from the mouth to the anus. Rare gastrointestinal illnesses can be somewhat uncomfortable, severe, or even fatal. Achalasia, celiac disease, Ménétrier disease, Crohn's disease, and gastroesophageal reflux disease are some instances of gastrointestinal illnesses.
Continuous advances in medical research, such as a greater understanding of illness genetic and molecular bases, can lead to the identification of novel therapy targets for uncommon gastrointestinal diseases. These discoveries may pique the interest of both researchers and pharmaceutical corporations in developing tailored medicines. Furthermore, rising government initiatives and spending on gastrointestinal disease treatment are boosting market expansion.
However, the pharmaceutical supply chain experienced disruption, potentially affecting the availability of drugs and treatments for uncommon gastrointestinal disorders during a pandemic. The high costs associated with the research and development of pipeline candidates used for the treatment of rare diseases may stymie market expansion, contributing to the rise in drug prices.
Recent Developments:
- In May 2022, Eli Lilly and Company started the CONFIDE Study to learn more about the prevalence of inflammatory bowel illnesses and how they impact patients. The organization created the CONFIDE portal to better understand how gastrointestinal illnesses impact patients' physical and mental health. The business also intends to provide patients with individualized therapy.
- In May 2020, Teva Pharmaceutical Industries Ltd. made an announcement regarding the approval of AUSTEDO® (Deutetrabenazine Tablets) by the China National Medical Products Administration (NMPA). This approval, which followed a priority review, pertains to the use of AUSTEDO® in the treatment of chorea associated with Huntington's disease (HD) and Tardive Dyskinesia (TD) in adults. China has become the second nation, following the United States, to provide approval for the usage of AUSTEDO.
Competitive Landscape
Some Major Key Players In The Rare Gastrointestinal Diseases Treatment Market:
- Bayer Pharmaceutical Corp
- Teva Pharmaceutical
- Novartis AG
- Sanofi
- Pfizer, Inc.
- GlaxoSmithKline PLC
- Eli Lilly and CO.
- Johnson & Johnson
- Others
Market Segmentation:
The Rare Gastrointestinal Diseases Treatment Market is segmented on the basis of treatment and end-user. As per the treatment, the market is segmented into medications and nutritional support. The end-user segment includes hospitals, research institutes, and others.
Based On Treatment, The Medications Segment Is Accounted As A Major Contributor In The Rare Gastrointestinal Diseases Treatment Market
The medications category is expected to hold a major share in the global Rare Gastrointestinal Diseases Treatment Market in 2022. Many rare gastrointestinal disorders qualify for orphan drug classification, which provides pharmaceutical companies with incentives to discover therapies. These advantages include prolonged market exclusivity, tax breaks, and lower regulatory fees, all of which encourage investment in R&D. Because of the tiny patient population for uncommon gastrointestinal disorders, the perceived market size and income potential for drugs can be influenced.
The Hospital Segment Witnessed Rapid Growth
The hospital is projected to grow at a rapid rate in the global Rare Gastrointestinal Diseases Treatment Market. Hospitals frequently collaborate on research projects with academic institutions, pharmaceutical corporations, and patient advocacy organizations. These collaborations propel research and treatment innovation. Advanced diagnostic tools, genetic testing, molecular imaging, and specialized endoscopic methods are frequently available in specialized facilities. Accurate diagnosis is essential for customizing treatment regimens.
In The Region, The North America Rare Gastrointestinal Diseases Treatment Market Holds A Significant Revenue Share
The North American rare Gastrointestinal Diseases Treatment Market is expected to record the maximum market share in terms of revenue in the near future. This can be attributed to the increase in patients experiencing uncommon gastrointestinal illnesses. This is due to remarkable lifestyle changes, which have resulted in stomach ulcers, bleeding, haemorrhoids, and anaemia, among other things. Furthermore, government programs aimed at preventing and treating gastrointestinal illnesses are projected to drive the market.
Moreover, Asia Pacific is estimated to grow at a significant rate over the forecast period. The increased recognition of the global market potential for rare illness medicines is prompting pharmaceutical corporations to invest in R&D.
Rare Gastrointestinal Diseases Treatment Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 1.29 Bn |
|
Revenue Forecast In 2031 |
USD 1.68 Bn |
|
Growth Rate CAGR |
CAGR of 3.1% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Treatment, End-user |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Bayer Pharmaceutical Corp, Teva Pharmaceutical, Novartis AG, Sanofi, Pfizer, Inc., GlaxoSmithKline PLC, Eli Lilly and CO., Johnson & Johnson, and others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
